Skip to main content

Advertisement

Table 3 Prognostic factors associated with OS

From: A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Variables Univariate Multivariate
HR(95%CI) P value HR(95%CI) P value
Age (y) (≤ 55, > 55) 0.96(0.81–1.22) 0.413   
Gender (male/female) 1.25(0.89–1.42) 0.319   
HBsAg (positive/ negative) 0.97(0.78–1.22) 0.8   
ALB, g/L (≤ 35, > 35) 0.71(0.59–0.85) < 0.001   
TBIL, μmol/L (≤ 28, > 28) 1.65(1.33–2.04) < 0.001 1.64(1.17–2.29) 0.004
ALT, IU/L (≤ 40 > 40) 1.34(1.13–1.59) 0.001   
AST, IU/L (≤ 35 > 35) 2.01(1.64–2.47) < 0.001   
PT, sec (≤ 12/ > 12) 1.13(0.95–1.34) 0.173   
AFP, ng/mL (≤ 400/ > 400) 1.58(1.34–1.87) < 0.001   
Child-pugh grade (A/ B) 1.34(1.09–1.66) 0.006   
MELD score (≤ 10/ >  10) 1.45(1.09–1.91) 0.008   
Largest tumor size (cm) (≤ 10/ > 10) 1.75(1.40–2.19) < 0.001   
Tumor number (single/multiple) 1.01(0.83–1.23) 0.992   
Vascular invasion (present/ absent) 2.02(1.61–2.54) < 0.001   
BCLC (B / C stage) 2.21(1.76–2.77) < 0.001 1.65(1.24–2.19) 0.001
dNLR (≤ 1.7, > 1.7) 2.17(1.79–2.61) < 0.001   
PNI (≤ 46, > 46) 0.66(0.56–0.78) < 0.001   
TACE treatments (1/ 2/ > 1)
 1    
 2 1.94(1.58–2.37) < 0.001 2.39(1.69–3.38) < 0.001
 > 2 1.52(1.21–1.91) < 0.001 1.39(0.96–2.03) 0.078
dNLR-PNI
 0    
 1 1.62(1.25–2.09) < 0.001 1.71(1.08–2.68) 0.022
 2 2.75(2.14–3.53) < 0.001 3.25(1.74–6.02) < 0.001
  1. dNLR derived neutrophil-to-lymphocyte ratio, PNI prognostic nutritional index, WBC white blood cells, BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, ALB albumin, PT Prothrombin time, INR international normalized ratio, HBsAg hepatitis B surface antigen, AFP α-fetoprotein, TBIl total bilirubin, MELD the model for end stage liver disease, BCLC barcelona clinic liver cancer